Syon Capital’s Dyne Therapeutics DYN Stock Holding History

Syon Capital’s Portfolio DYN Stock Details DYN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-16,930	Closed	-$399K	–	603
2024 Q4	$399K	Buy	+16,930	New	+$501K	0.04%	339

Other funds holding DYN

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

AVLSA

Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

FIS

FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Syon Capital's DYN Position: Q1 2025 in Review

Syon Capital sold out of Dyne Therapeutics (DYN) in Q1 2025, closing a stake of 16,930 shares — an estimated $399K sold.

Syon Capital first reported a position in DYN in Q4 2024 and held it in 1 quarter. The position peaked at $399K in Q4 2024. 205 funds tracked by Wall St. Rank hold DYN as of Q1 2025.

Syon Capital reported no remaining Dyne Therapeutics position as of Q1 2025 after selling out during the quarter.
Syon Capital sold 16,930 Dyne Therapeutics shares in Q1 2025, an estimated $399K.
Syon Capital first reported a position in Dyne Therapeutics in Q4 2024 and held it in 1 quarter.
Syon Capital's Dyne Therapeutics position peaked at $399K in Q4 2024.
205 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q1 2025.

Based on Syon Capital's 13F filing for Q1 2025, filed 15 May 2025.